Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC
Status:
Terminated
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the 2-month progression-free survival in patients with
advanced or metastatic, non-squamous cell lung cancer treated with weekly low dose docetaxel
in combination with a biologic dose of sorafenib.